Cytosorbents Corporation
$0.65
▲
6.52%
2026-04-21 06:17:01
www.cytosorbents.com
NCM: CTSO
Explore Cytosorbents Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$41.24 M
Current Price
$0.65
52W High / Low
$1.39 / $0.5
Stock P/E
—
Book Value
$0.09
Dividend Yield
—
ROCE
-41.3%
ROE
-96.39%
Face Value
—
EPS
$-0.13
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
129
Beta
1.48
Debt / Equity
493.16
Current Ratio
2.12
Quick Ratio
1.58
Forward P/E
—
Price / Sales
1.03
Enterprise Value
$61.11 M
EV / EBITDA
-4.79
EV / Revenue
1.65
Rating
Buy
Target Price
$5.25
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biomerica, Inc. | $2.18 | — | $6.74 M | — | -122.16% | -84.3% | $4.6 / $1.87 | $1.5 |
| 2. | Rapid Micro Biosystems, Inc. | $2.25 | — | $103.66 M | — | -84.08% | -86.82% | $4.94 / $2.01 | $0.75 |
| 3. | GE HealthCare Technologies Inc. | $71.58 | 15.76 | $32.85 B | 0.19% | 9.93% | 22.38% | $89.77 / $59.95 | $22.77 |
| 4. | Adagio Medical Holdings, Inc. | $1.53 | — | $34.43 M | — | -62.51% | -1.55% | $2.87 / $0.74 | $0.56 |
| 5. | Aethlon Medical, Inc. | $2.39 | — | $3.67 M | — | -171.08% | -2.09% | $35.2 / $1.36 | $6.9 |
| 6. | Viemed Healthcare, Inc. | $9.66 | 24.97 | $372.9 M | — | 13.1% | 11.11% | $10.06 / $5.93 | $3.72 |
| 7. | Baird Medical Investment Holdings Limited | $1.79 | 55.75 | $64.64 M | — | 35.34% | -8.03% | $7.26 / $0.76 | $1.34 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 9.23 M | 9.48 M | 9.62 M | 8.73 M | 9.15 M | — |
| Operating Profit | -3.88 M | -2.86 M | -3.62 M | -3.89 M | -4.05 M | — |
| Net Profit | -5.5 M | -3.17 M | 1.95 M | -1.48 M | -7.88 M | — |
| EPS in Rs | -0.09 | -0.05 | 0.03 | -0.02 | -0.13 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 37.06 M | 35.59 M | 31.08 M | 29.36 M |
| Operating Profit | -14.24 M | -16.45 M | -31.95 M | -31.52 M |
| Net Profit | -8.2 M | -20.72 M | -29.25 M | -32.81 M |
| EPS in Rs | -0.13 | -0.33 | -0.47 | -0.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 44.18 M | 47.37 M | 52.96 M | 63.23 M |
| Total Liabilities | 38.28 M | 36.27 M | 29.48 M | 27.86 M |
| Equity | 5.9 M | 11.11 M | 23.48 M | 35.37 M |
| Current Assets | 20.63 M | 21.6 M | 25.4 M | 33.76 M |
| Current Liabilities | 9.71 M | 9.82 M | 14.04 M | 9.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -12.38 M | -14.43 M | -21.66 M | -28.23 M |
| Investing CF | -0.41 M | -0.67 M | -0.94 M | -6.46 M |
| Financing CF | 9.31 M | 9.33 M | 14.47 M | 4.96 M |
| Free CF | -12.87 M | -15.1 M | -22.59 M | -34.69 M |
| Capex | -0.49 M | -0.67 M | -0.94 M | -6.46 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 14.51% | 5.88% | — | — |
| Earnings Growth % | 29.16% | 10.87% | — | — |
| Profit Margin % | -58.21% | -94.09% | -111.76% | — |
| Operating Margin % | -46.22% | -102.78% | -107.36% | — |
| Gross Margin % | 69.92% | 70.62% | 52.47% | — |
| EBITDA Margin % | -54.13% | -89.69% | -103.51% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.